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Birth weight variation is influenced by fetal and maternal genetic and non-genetic factors, and has been reproducibly asso-
ciated with future cardio-metabolic health outcomes. In expanded genome-wide association analyses of own birth weight 
(n = 321,223) and offspring birth weight (n = 230,069 mothers), we identified 190 independent association signals (129 of 
which are novel). We used structural equation modeling to decompose the contributions of direct fetal and indirect mater-
nal genetic effects, then applied Mendelian randomization to illuminate causal pathways. For example, both indirect maternal 
and direct fetal genetic effects drive the observational relationship between lower birth weight and higher later blood pres-
sure: maternal blood pressure-raising alleles reduce offspring birth weight, but only direct fetal effects of these alleles, once 
inherited, increase later offspring blood pressure. Using maternal birth weight-lowering genotypes to proxy for an adverse 
intrauterine environment provided no evidence that it causally raises offspring blood pressure, indicating that the inverse birth 
weight–blood pressure association is attributable to genetic effects, and not to intrauterine programming.
Maternal and fetal genetic effects on birth weight 
and their relevance to cardio-metabolic risk factors
Birth weight is an important predictor of newborn and infant survival, is a key indicator of pregnancy outcomes, and is observationally associated with future risk of adult cardio-
metabolic diseases in offspring. These observational associations 
are often assumed to reflect adaptations made by a develop-
ing fetus in response to an adverse intrauterine environment—a 
concept termed the developmental origins of health and disease 
(DOHaD)1. Support for DOHaD is primarily from animal mod-
els (reviewed in ref. 2). Observational studies of famine-exposed 
populations support prenatal programming in relation to type 2 
diabetes (T2D), but not other cardio-metabolic health measures 
(reviewed in ref. 3). However, DOHaD cannot provide a complete 
explanation for the relationship between lower birth weight and 
increased risk of cardio-metabolic disease. Other probable con-
tributing factors are (1) environmental confounding, leading to 
phenotypic associations across the life-course4 and (2) shared 
genetic effects operating at the population level5. Genetic asso-
ciations between birth weight and later cardio-metabolic diseases 
may arise from the direct effects of the same inherited genetic 
variants at different stages of the life-course6. However, consider-
ation of an individual’s own genotype in isolation cannot exclude 
potential confounding by any indirect effects of the correlated 
maternal genotype (r = ~0.5) on the intrauterine, and possibly 
postnatal, environment. Evidence for indirect maternal effects on 
birth weight and later offspring disease risk could implicate the 
intrauterine environment in later-life disease etiology.
To date, 65 genetic loci have been associated with birth weight 
in genome-wide association studies (GWASs), implicating bio-
logical pathways that may underlie observational associations with 
adult disease5,7–9. However, most of these studies did not distin-
guish between maternal and fetal genetic influences. Evidence from 
monogenic human models10 and variance component analyses11 
demonstrates that birth weight is influenced by genotypes inherited 
by the fetus and by maternal genotypes that influence the intrauter-
ine environment. To date, GWASs of own birth weight5 and mater-
nal GWASs of offspring birth weight7 have produced overlapping 
signals due to the correlation between maternal and fetal genotypes. 
Identified birth weight variants might have (1) a direct fetal effect 
only; (2) an indirect maternal effect only; or (3) some combination 
of the two. Performing separate GWAS analyses of own or offspring 
birth weight precludes full resolution of the origin of the identified 
genetic effects.
To address these issues, we performed greatly expanded GWASs 
of own (n = 321,223) and offspring birth weight (n = 230,069 moth-
ers) using data from the Early Growth Genetics (EGG) Consortium 
and the UK Biobank (2017 release). We applied a structural equa-
tion model that we recently developed to partition genetic effects 
on birth weight into maternal and fetal components at genome-
wide-significant loci7,12. We then extended the method to estimate 
maternal- and fetal-specific genetic effects across the genome in a 
computationally efficient manner, and used the results for down-
stream analyses. Our ability to resolve maternal and fetal genetic 
contributions provides substantial insights into the underlying bio-
logical regulation of birth weight, as well as the origins of observa-
tional relationships with T2D and blood pressure.
Results
Meta-analyses of fetal and maternal GWASs. We conducted 
GWAS meta-analyses of own (fetal) genetic variants on own 
birth weight (Supplementary Fig.  1 and Supplementary Tables  1 
and 2) and maternal genetic variants on offspring birth weight 
(Supplementary Fig. 2 and Supplementary Tables 3 and 4) in indi-
viduals of European ancestry. We then performed approximate con-
ditional and joint multiple single-nucleotide polymorphism (SNP) 
analyses (COJO13) and a trans-ethnic meta-analysis to identify fur-
ther independent SNPs (Methods). The GWAS meta-analysis of 
own birth weight (n = 321,223) identified 146 independent SNPs at 
genome-wide significance (P < 6.6 × 10−9; Supplementary Figs. 3, 4 
and 5a, Supplementary Table 5a and Methods). The GWAS meta-
analysis of offspring birth weight (n = 230,069 mothers) identified 
72 independent SNPs (P < 6.6 × 10−9; Supplementary Figs. 3, 4 and 
5b, Supplementary Table  5a and Methods). Applying the more 
lenient significance threshold used previously (P < 5 × 10−8)5,7, 211 
and 105 SNPs reached significance for own and offspring birth 
weight, respectively (Supplementary Table 5b).
SNPs at 30 genome-wide-significant loci (within 500 kilobases 
(kb) and linkage disequilibrium (LD) r2 ≥ 0.1) were identified in the 
GWASs of both own and offspring birth weight. Of these, 9 loci had 
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the same lead SNP and 21 loci had correlated fetal and maternal 
lead SNPs (r2 ≥ 0.1). Colocalization analysis indicated that 19/21 
of these correlated lead SNP pairs were probably tagging the same 
birth weight signal (posterior probability > 0.5). Therefore, we iden-
tified a total of 190 independent association signals, represented by 
209 lead SNPs (Supplementary Fig. 4 and Supplementary Table 5a). 
Of the 209 lead SNPs, 146 are novel (representing 129 independent 
association signals), 3 are rare (minor allele frequency (MAF) < 1%) 
and 13 are low frequency (1% ≤ MAF < 5%). The three rare vari-
ants (at the YKT6/GCK, ACVR1C and MIR146B loci) alter birth 
weight by more than double the effect (>100 g per allele) of the 
first common variants identified9. In the independent Norwegian 
Mother and Child Cohort Study (MoBa–HARVEST; n = 13,934 
mother–offspring duos), the lead SNPs explained 7% of the vari-
ance in birth weight, calculated as the sum of variances explained by 
the fetal genotype (6%) and maternal genotype (2%), plus twice the 
covariance (−0.5%). Maternal genome-wide complex trait analysis 
(M-GCTA11), which estimates SNP heritability, and partitions this 
quantity into maternal and fetal components, estimated that 39.8% 
of the variance in birth weight could be explained by tagged fetal 
genetic variation (28.5%), tagged maternal genetic variation (7.6%) 
and twice the covariance (3.7%).
We integrated data from several sources to highlight possible 
causal genes underlying the identified associations, including 
gene-level expression data across 43 tissues (from GTEx version 
6p14), placental expression quantitative trait loci (eQTL)15, topo-
logically associating domains (TADs) identified in human embry-
onic stem cells16,17 and non-synonymous SNPs (see Supplementary 
Table 5a,b and Methods). Several genes were highlighted by mul-
tiple approaches; however, further functional studies are required 
to confirm causality.
Structural equation model to estimate maternal and fetal effects. 
Next, we partitioned the 209 lead SNPs into 5 categories based on 
their maternal and/or fetal genetic contributions to birth weight. 
To achieve this, we used structural equation modeling (SEM), 
which accounts for the correlation between fetal and maternal 
genotypes and thereby provides unbiased estimates of the mater-
nal and fetal genetic effects on birth weight12 (see Methods and 
Supplementary Fig.  6a for details). The results are presented in 
Fig.  1, Supplementary Figs.  4 and 7 and Supplementary Table  5. 
Using the confidence intervals (CIs) around the SEM-adjusted 
maternal and fetal effect estimates, we identified 64 SNPs with 
fetal-only effects, 32 SNPs with maternal-only effects, 27 SNPs with 
directionally concordant fetal and maternal effects and 15 SNPs with 
directionally opposing fetal and maternal effects (Supplementary 
Fig. 8). For example, rs10830963 at MTNR1B was identified in both 
the own-birth-weight (P = 2.8 × 10−11) and offspring-birth-weight 
GWAS (P = 9.1 × 10−39), but the SEM analysis revealed that its effect 
was exclusively maternal (PSEMfetal = 0.7; PSEMmaternal = 4.6 × 10−19). 
In contrast, rs560887 at G6PC2 was identified only in the GWAS 
of offspring birth weight (P = 1.2 × 10−14), but was found to have 
directionally opposing maternal and fetal effects (βSEMfetal = −0.03; 
PSEMfetal = 2.8 × 10−8; βSEMmaternal = 0.04; PSEMmaternal = 5.4 × 10−14). At 
present, these categories are suggestive, as the current sample size 
has insufficient statistical power to detect small genetic effects, par-
ticularly maternal effects. Some SNPs that were classified as fetal 
only may have had a small undetected maternal effect. In addition, 
71 SNPs remained unclassified. Asymptotic power calculations 
showed that we had 80% power to detect fetal (maternal) effects 
that explained 0.006% (0.008%) of the variance in birth weight 
(α = 0.05). However, there was strong consistency with traditional 
conditional linear regression modeling in n = 18,873 mother–off-
spring pairs (Supplementary Table 6 and Methods), and overall, the 
method gave a clear indication as to which genetic associations are 
driven by the maternal or fetal genomes.
To extend the estimates of adjusted maternal and fetal effects 
genome wide, we developed a weighted linear model (WLM) (see 
Methods), which yields a good approximation to the SEM with 
equivalent estimates for the 209 lead SNPs (Supplementary Fig. 9). 
This was necessary because the SEM is too computationally inten-
sive to fit across the genome. The adjusted fetal and maternal geno-
type effect estimates on birth weight from the WLM are hereafter 
referred to as WLM-adjusted estimates. Using linkage disequilib-
rium score regression18, we observed that the genetic correlation 
between the WLM-adjusted maternal and fetal effects (rg = 0.10; 
P = 0.12) was substantially lower than that between the unadjusted 
effects from the original GWAS (rg = 0.82; P < 0.01), indicating that 
the WLM largely accounts for the underlying correlation between 
fetal and maternal genotypes. No additional novel loci were iden-
tified, but we used the WLM-adjusted estimates in downstream 
analyses to identify fetal- and maternal-specific mechanisms that 
regulate birth weight, and to investigate the genetic links between 
birth weight and adult traits.
Maternal- and fetal-specific tissues and mechanisms underly-
ing birth weight regulation. Tests of global enrichment of birth 
weight SNP associations across tissues sampled from the GTEx 
project14 using LD-SEG19 are presented in Supplementary Fig. 10. 
Only enrichment for maternal-specific SNP associations for genes 
expressed in connective/bone tissues was detected after Bonferroni 
correction. Integration of epigenetic signatures defined by the 
Roadmap Epigenomics Project highlighted a significant enrichment 
of maternal-specific effects in the ovary for histone modification 
marks (H3K4me1) and regions of open chromatin (Supplementary 
Table  7); no significant enrichment was detected for other signa-
tures. Gene set enrichment analysis implicated different fetal- 
(Supplementary Table  8) and maternal-specific (Supplementary 
Table 9) gene sets.
A major determinant of birth weight is the duration of gestation. 
Using linkage disequilibrium score regression18, we found a substan-
tial genetic correlation between published maternal genetic effects 
on gestational duration20 and the WLM-adjusted maternal effects 
on offspring birth weight (rg = 0.63; P = 2.1 × 10−5; Supplementary 
Table 10 and Methods), but not with the WLM-adjusted fetal effects 
on own birth weight (rg = −0.10; P = 0.34). Gestational duration 
was unavailable for >85% of individuals in the birth weight GWAS 
analyses, so it is possible that some identified association signals 
influence birth weight primarily by altering gestational duration. 
We looked up the 209 lead birth-weight-associated SNPs in the pub-
lished maternal GWAS of gestational duration20 (Supplementary 
Table  11) and followed up 7 associated SNPs (P < 2.4 × 10−4, cor-
rected for 209 tests; Methods) in 13,206 mother–child pairs. 
Meta-analysis with summary data from 23andMe20 strengthened 
associations with gestational duration at five of seven loci (EBF1, 
AGTR2, ZBTB38, KCNAB1 and KLHL25/AKAP13; Supplementary 
Table  12). The precise causal relationship between fetal growth 
and gestational duration at these loci requires further investiga-
tion; however, the majority of associations with birth weight do not 
appear to be driven by associations with gestational duration.
Maternal- and fetal-specific genetic correlations between birth 
weight and adult traits. The 209 lead birth-weight-associated 
SNPs were associated with other phenotypes in previously pub-
lished GWASs and the UK Biobank (Supplementary Table 13 and 
Methods). At the genome-wide level, we previously reported genetic 
correlations between own birth weight and several adult cardio-
metabolic traits5, but were unable to distinguish the direct fetal 
genotype contribution from the indirect contribution of maternal 
genotype. To understand these distinct contributions, we calculated 
genetic correlations using linkage disequilibrium score regression18 
between WLM-adjusted fetal and maternal SNP effect estimates 
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and GWAS estimates for a range of traits (Fig.  2, Supplementary 
Table 10 and Methods). For many traits (for example, adult height), 
the fetal-specific genetic correlation was similar to the maternal-
specific genetic correlation, but for some traits, the fetal- and 
maternal-specific genetic correlations were different in magnitude 
(for example, systolic blood pressure (SBP)) or even in direction (for 
example, T2D). For several glycemic traits (for example, fasting glu-
cose), the genetic correlations estimated using the WLM-adjusted 
effects were substantially different from those estimated using the 
unadjusted effects, showing the importance of accounting for the 
maternal–fetal genotype correlation.
Using genetics to estimate causal effects of intrauterine exposures 
on birth weight. The separation of direct fetal genotype effects from 
indirect maternal genotype effects on birth weight offers the novel 
opportunity to estimate unconfounded causal influences of intra-
uterine exposures by using Mendelian randomization analyses. The 
principle of Mendelian randomization is similar to that of a ran-
domized controlled trial: parental alleles are randomly transmitted 
to offspring and are therefore generally free from confounding21,22. 
Consequently, an association between a maternal genetic variant for 
an exposure of interest, and offspring birth weight, after account-
ing for fetal genotype, provides evidence that the maternal expo-
sure is causally related to offspring birth weight (Fig. 3a). Previous 
attempts to estimate causal effects of maternal exposures on off-
spring birth weight were limited by an inability to adjust for fetal 
genotype in adequately powered samples23, which can now be over-
come by using WLM-adjusted estimates. We applied two-sample 
Mendelian randomization24 to estimate causal effects of maternal 
exposures on offspring birth weight, focusing on height, glycemic 
traits and blood pressure. We selected SNPs known to be associ-
ated with each exposure, and regressed the WLM-adjusted maternal 
effects on birth weight for those SNPs against the effect estimates for 
the maternal exposure, weighting by the inverse of the variance of 
the maternal exposure effect estimates. In the same way, we used the 
WLM-adjusted fetal effects to estimate the casual effect of the off-
spring’s genetic potential on their own birth weight, and compared 
the results with the estimated maternal causal effects.
Height and birth weight. Classical animal experiments25 showed 
that larger maternal size can support greater fetal growth. This is 
supported by observational human data showing that offspring 
height shifts from being closer to the maternal than the paternal 
height percentile in infancy towards mid-parental height in adult-
hood, the latter reflecting the predominant role of inherited genetic 
variation26. However, several observational studies have provided 
mixed evidence regarding correlations between maternal or pater-
nal height and offspring birth weight. Some studies show a stronger 
correlation with maternal than paternal height27,28, which would 
be consistent with a role for intrauterine effects, while others show 
that maternal and paternal height are both strongly correlated with 
offspring birth weight29–31. The Mendelian randomization analysis, 
using 693 height-associated SNPs32 (Supplementary Table 14), esti-
mated that a 1 s.d. (6 cm) higher maternal height is causally associ-
ated with a 0.11 s.d. (95% CI: 0.10 to 0.13) higher offspring birth 
weight (Fig. 3b), independent of the direct fetal effects. A similar 
estimate was obtained using the WLM-adjusted fetal effects on own 
birth weight (0.11 s.d. (95% CI: 0.09 to 0.13)), reflecting the role of 
inherited height alleles (Supplementary Table 15). Both a previous 
study33 and complementary analysis using transmitted and non-
transmitted height alleles in mother–offspring pairs estimated a 
much larger contribution of direct fetal effects than indirect mater-
nal effects to offspring birth weight (Supplementary Table 16 and 
Methods), but with relatively small sample sizes. In contrast with 
a previous report33, there was little supportive evidence that the 
maternal height effect on birth weight was via prolonged gestation 
(P = 0.12; Supplementary Table 15). These Mendelian randomiza-
tion results are consistent with the hypothesis that greater maternal 
height causally increases birth weight, and that this effect is inde-
pendent of the direct birth weight-raising effect of height alleles 
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inherited by the fetus. Although greater availability of space for fetal 
growth is a possible explanation, we cannot rule out other causal 
pathways. For example, causal associations between greater height 
and a more favorable socio-economic position34 could enhance 
maternal nutritional status and result in higher offspring birth 
weight. We also cannot exclude the contribution of assortative mat-
ing35 to these results: correlation between maternal and paternal 
height genotypes could lead to similar maternal and fetal Mendelian 
randomization estimates.
Glycemic traits and birth weight. Maternal glucose is a key deter-
minant of fetal growth: it crosses the placenta, stimulating the 
production of fetal insulin, which promotes growth36. As a con-
sequence, strong positive associations are seen between maternal 
fasting glucose, fetal insulin levels and offspring birth weight37. In 
a randomized clinical trial of women with gestational diabetes mel-
litus, glucose control was shown to reduce offspring birth weight38. 
Therefore, we anticipated detecting a positive causal effect of 
maternal glucose on offspring birth weight, as previously observed 
using Mendelian randomization in a smaller sample23. Indeed, the 
Mendelian randomization analysis using 33 fasting glucose-associ-
ated SNPs (Supplementary Table 14) estimated a 0.18 s.d. (95% CI: 
0.13 to 0.23) higher offspring birth weight due to 1 s.d. (0.4 mmol l−1) 
higher maternal fasting glucose, independent of the direct fetal 
effects (Supplementary Table  15 and Fig.  3c). A large part of the 
genetic variation underlying fasting glucose levels is implicated in 
pancreatic β-cell function and thus overlaps with the genetics of 
insulin secretion. To estimate the causal effect of insulin secretion 
on birth weight, we used 18 SNPs associated with the disposition 
index—a measure of insulin’s response to glucose, adjusted for insu-
lin sensitivity. Alleles that increase insulin secretion in the mother 
tend to decrease her glucose levels, which consequently reduces 
insulin-mediated growth of the fetus. This was reflected in the neg-
ative causal estimate from the Mendelian randomization analysis 
of the effect of the maternal disposition index on offspring birth 
weight (−0.17 s.d. per 1 s.d. higher maternal disposition index (95% 
CI: −0.26 to −0.08); Supplementary Table 15). In contrast, we esti-
mated that birth weight was 0.10 s.d. (95% CI: 0.02 to 0.19) higher 
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Fig. 2 | Genome-wide genetic correlation between birth weight and a range of traits and diseases in later life. Genetic correlation (rg) between birth 
weight and the traits, and corresponding 95% CIs, were estimated using linkage disequilibrium score regression in LD Hub. Genetic correlations were 
estimated from the summary statistics of the WLM-adjusted fetal GWAS (WLM-adjusted fetal effect on own birth weight) and WLM-adjusted maternal 
GWAS (WLM-adjusted maternal effect on offspring birth weight). The total sample size included in the WLM-adjusted GWAS was 406,063 individuals 
with their own and/or their offspring’s birth weight. The genetic correlation estimates are color coded according to their intensity and direction (red, 
positive correlation; blue, negative correlation). ADHD, attention deficit hyperactivity disorder; HbA1c, hemoglobin A1c; HOMA-B, homeostasis model 
assessment of β-cell function; HOMA-IR, homeostasis model assessment of insulin resistance. See Supplementary Table 10 for the references for each of 
the traits and diseases displayed, as well as the genetic correlation results for other traits and diseases.
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Fig. 3 | Mendelian randomization to assess the causal effect of maternal intrauterine exposures on offspring birth weight (adapted from Lawlor et al.45). 
a, Since maternal and fetal genotypes are correlated, it is essential to account for offspring genotype in this analysis. The continuous, thin arrow 
represents the relationship between the genetic instrument and intrauterine exposure. The dashed arrows represent potential confounding via maternal 
characteristics, which, under Mendelian randomization assumptions, are not associated with the genetic instrument. The dotted arrows represent 
potential violation of Mendelian randomization assumptions via offspring genotype. The thick arrow represents the causal effect of interest. b, Higher 
offspring birth weight is caused by direct fetal genetic effects of height-raising alleles and indirect effects of maternal height-raising alleles. Indirect 
maternal effects of height-raising alleles may increase offspring birth weight by increasing the space available for growth, but we cannot rule out 
alternative explanations; for example, assortative mating. c, Higher maternal fasting glucose levels increase offspring birth weight. Conversely, direct fetal 
genetic effects of glucose-raising alleles reduce birth weight. This is probably due to their effects on insulin: variants that lower maternal insulin levels 
increase maternal glucose, which crosses the placenta and stimulates fetal insulin-mediated growth. However, the same variants in the fetus cause lower 
fetal insulin levels, and consequently, reduced fetal insulin-mediated growth. d, Higher maternal SBP is causally associated with lower offspring birth 
weight. After adjusting for maternal effects, there was no evidence of an effect of offspring’s own SBP genetic score on own birth weight. BW, birth weight; 
FPG, fasting plasma glucose; SEP, socio-economic position. 1 s.d. of BW = 484 g (refs. 9,45).
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per 1 s.d. genetically higher fetal disposition index (Methods), high-
lighting that genetic variation underlying insulin secretion plays a 
key role in fetal growth, and suggesting that the genetic effects on 
the disposition index are similar in fetal and adult life.
Birth weight associations with previously reported GWAS SNPs 
for fasting glucose, T2D, insulin secretion and insulin sensitivity loci 
were directionally consistent with the overall genetic correlations, 
and supported the opposing contributions of fetal versus maternal 
glucose-raising alleles on birth weight (Supplementary Figs. 11–14). 
Taken together with the WLM-adjusted genetic correlations, the 
Mendelian randomization results underline the importance of fetal 
insulin in fetal growth, and show that fetal genetic effects link lower 
birth weight with reduced insulin secretion and higher T2D risk in 
later life6. However, further work is needed to investigate the role of 
indirect maternal genetic effects in the relationship between high 
birth weight and higher future risk of T2D.
Blood pressure and birth weight. Observational studies of the 
relationship between birth weight and later-life blood pressure have 
produced mixed findings. Some studies indicate that lower birth 
weight is associated with higher later-life blood pressure and related 
comorbidities39, whereas others have shown that this relationship 
could be driven by a statistical artifact due to adjusting for current 
weight40,41. We have previously shown that genetic factors account 
for a large proportion of an association between lower birth weight 
and higher blood pressure5, but it was not clear whether this was 
due to direct fetal genotype effects or indirect maternal effects, or a 
combination of the two. We explored this association further using 
several complementary analyses. The estimate of the birth weight–
SBP covariance explained was higher when using the maternal gen-
otyped SNP associations with offspring birth weight (65% (95% CI: 
57 to 74%)) than when using the fetal genotype associations with own 
birth weight (56% (95% CI: 48 to 64%); Supplementary Table 17). A 
similar pattern was seen with the birth weight–diastolic blood pres-
sure (DBP) covariance (maternal: 72% (95% CI: 58 to 85%); fetal: 
56% (95% CI: 46 to 67%); Supplementary Table 17). Together with 
the larger maternal than fetal genetic correlation for SBP (Fig. 2), 
these results point to the importance of indirect maternal effects of 
Maternal
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fetal growth
Maternal BW genetic
score
Maternal SEP and lifestyle
(for example, diet, physical activity and
smoking)
Offspring genotype
Offspring adult
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b
Fig. 4 | Mendelian randomization to assess the causal effect of intrauterine growth on offspring adult outcomes, using maternal intrauterine 
exposures that influence fetal growth. a, Maternal genotype should be associated with offspring birth weight independent of offspring genotype, so 
it is essential to adjust the analysis for offspring genotype. The continuous, thin arrow represents the relationship between the genetic instrument and 
intrauterine exposure. The long-dashed arrows denote the (maternal and possibly fetal) genotype associations with birth weight; these arrows highlight 
the assumption that genetic variation influences offspring adult outcome via intrauterine growth, not birth weight. The short-dashed arrows represent 
potential confounding via maternal and offspring characteristics. The dotted arrow represents potential violation of assumptions of the Mendelian 
randomization analysis via offspring genotype. The thick arrow represents the causal effect of interest. We have not estimated the size of the causal effect 
as we do not have effect estimates for the SNP-maternal intrauterine exposures influencing fetal growth. However, we have used the presence versus 
absence and direction of association in 3,886 mother–offspring pairs to indicate whether the intrauterine environment causes changes in adult offspring 
SBP (see Supplementary Table 18 for full results). b, Our results show that the observed negative correlation between birth weight and later SBP may be 
driven by the causal effect of higher maternal SBP on lower offspring birth weight (red arrow), in combination with the subsequent transmission of SBP-
associated alleles to offspring (blue arrow), which then increase offspring SBP.
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blood pressure on offspring birth weight (Supplementary Figs. 15 
and 16). In line with this, Mendelian randomization analyses indi-
cated that a 1 s.d. (10 mmHg) higher maternal SBP is causally asso-
ciated with a 0.15 s.d. (95% CI: −0.19 to −0.11) lower offspring birth 
weight, independent of the direct fetal effects. In contrast, there was 
no fetal effect of SBP on own birth weight, after adjusting for the 
indirect maternal effect (−0.01 s.d. per 10 mmHg, 95% CI: −0.05 to 
0.03; Fig. 3d and Supplementary Tables 14 and 15). Similar results 
were seen in the WLM-adjusted Mendelian randomization analyses 
of DBP on offspring and own birth weight.
Estimating the causal effect of birth weight-lowering intrauterine 
exposures on offspring SBP. A key question is whether maternal 
SNPs that reduce offspring birth weight through intrauterine effects 
are also associated with higher SBP in their adult offspring. Such 
an association would suggest that the maternal intrauterine effects 
cause the later SBP effect (that is, through developmental adapta-
tions) (Fig. 4a and Supplementary Fig. 17). To investigate this pos-
sibility, we tested the conditional association between maternal 
and offspring genetic scores for birth weight and offspring SBP, as 
measured in 3,886 mother–offspring pairs in the UK Biobank, with 
sensitivity analyses in 1,749 father–offspring pairs. The fetal genetic 
score for lower birth weight was associated with higher offspring 
SBP, even after adjustment for maternal (or paternal) birth weight 
genotypes. However, when adjusted for fetal genotypes, the maternal 
genetic score for lower birth weight was associated with lower (not 
higher) offspring SBP (Supplementary Table  18). Taken together, 
our results show that the observed negative correlation between 
birth weight and later SBP is driven by (1) the causal effect of higher 
maternal SBP on lower offspring birth weight (Fig. 3d), in combina-
tion with (2) the subsequent transmission of SBP-associated alleles to 
offspring, which then increase offspring SBP (Fig. 4b), rather than by 
long-term developmental responses to adverse in utero conditions.
Discussion
In greatly expanded GWASs and follow-up analyses of own and off-
spring birth weight, we have identified 129 novel association signals 
and partitioned the genetic effects on birth weight into direct fetal 
and indirect maternal (intrauterine) effects. Using these partitioned 
effects, we identified fetal- and maternal-specific mechanisms and 
tissues involved in the regulation of birth weight, and mechanisms 
with directionally opposing effects in the fetus and mother (for 
example, insulin secretion and fasting glucose).
Mendelian randomization analyses using the WLM-adjusted 
estimates showed that (1) both direct fetal and indirect maternal 
effects of height-raising genotypes contribute to higher offspring 
birth weight; (2) fetal (and not maternal) genotype effects explain 
the negative genetic correlation between birth weight and later 
T2D; and (3) the negative genetic correlation between birth weight 
and adult SBP is the result of both indirect SBP-raising effects of 
maternal genotypes reducing offspring birth weight, and direct 
effects of fetal genotypes on higher adult SBP. The resolution of 
maternal versus fetal effects was higher in these Mendelian ran-
domization analyses than has previously been achieved using 
analyses of available mother–child pairs23, due to greater statisti-
cal power. Recently, a number of authors have attempted to use 
Mendelian randomization methodology to investigate causal links 
between birth weight and later T2D42–44. However, such naive 
Mendelian randomization analyses using two-sample approaches 
in unrelated sets of individuals, which do not properly account for 
the correlation between maternal and fetal genotype effects, may 
result in erroneous conclusions regarding causality. Future inves-
tigations into causal links between birth weight and later T2D or 
other disease outcomes will require larger samples than are cur-
rently available, with maternal and offspring genotypes and off-
spring later-life disease outcomes.
There are some limitations to this study (see Supplementary Note 
for a full discussion). First, the Mendelian randomization results 
concern birth weight variation within the normal range and do not 
necessarily reflect the effects of extreme environmental events (for 
example, famine), which may exert qualitatively different effects. 
Additionally, we have assumed a linear relationship between birth 
weight and later-life traits, which may be an oversimplification for 
some traits such as T2D. Second, birth weight is the end marker of a 
developmental process, with critical periods during the process that 
may make the fetus particularly sensitive to environmental influ-
ences. The Mendelian randomization analyses could therefore be 
masking effects at certain critical periods. Third, we have assumed 
that genetic variants identified in large GWASs of SBP and glycemic 
traits in males and non-pregnant females are similarly associated 
in pregnant women. Fourth, we have not investigated the poten-
tial gender difference in the associations between birth weight and 
later-life traits. Fifth, we have assumed that the critical period of 
exposure to indirect maternal genetic effects is pregnancy, and that 
the estimates do not reflect pre-pregnancy effects on primordial 
oocytes or postnatal effects45. Sixth, we have not considered paternal 
genotypes, and it is possible that this omission has biased the results 
of some of our analyses. Finally, although we were able to fit the full 
SEM at the 209 lead SNPs, we were unable to fit the SEM, including 
the 2 degrees of freedom test (that is, where maternal and fetal paths 
are constrained to 0) at all SNPs across the genome.
To conclude, the systematic separation of fetal from maternal 
genetic effects in a well-powered study has enhanced our under-
standing of the regulation of birth weight and of its links with later 
cardio-metabolic health. In particular, we show that the associa-
tion between lower birth weight and higher adult blood pressure is 
attributable to genetic effects, and not to intrauterine programming. 
In successfully separating maternal from fetal genetic effects and 
using them in Mendelian randomization analyses, this work sets a 
precedent for future studies seeking to understand the causal role of 
the intrauterine environment in later-life health.
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Methods
Ethics statement. All human research was approved by the relevant institutional 
review boards and conducted according to the Declaration of Helsinki. Participants 
of all studies provided written informed consent. The UK Biobank has approval 
from the North West Multi-Centre Research Ethics Committee, which covers the 
United Kingdom. Ethical approval for the Avon Longitudinal Study of Parents and 
Children (ALSPAC) study was obtained by the ALSPAC Ethics and Law Committee 
and local research ethics committees. Ethical approval for the Exeter Family Study of 
Childhood Health (EFSOCH) study was given by the North and East Devon Local 
Ethics Committee. Approval for access to data and biological material relating to 
MoBa–HARVEST was granted by the Scientific Management Committee of MoBa 
and the Regional Committee for Medical and Health Research Ethics.
Statistical tests. Details of the statistical tests used in the various analyses are 
reported under the appropriate headings below. All tests were two sided, unless 
otherwise stated.
GWAS of own birth weight. European ancestry meta-analysis. The European 
ancestry GWAS meta-analysis of own birth weight consisted of two components 
(Supplementary Fig. 1): (1) 80,745 individuals from 35 studies participating in the 
EGG Consortium from Europe, the United States and Australia; and (2) 217,397 
individuals of white European origin from the UK Biobank (see Supplementary 
Note for details on phenotype preparation and GWAS analyses). We combined the 
summary statistics from the EGG meta-analysis with the UK Biobank summary 
statistics using a fixed-effects meta-analysis in GWAMA46 (maximum n = 297,142). 
Variants failing GWAS quality-control filters, reported in <50% of the total 
sample size in the EGG component, or with MAF < 0.1% were excluded. We also 
performed a fixed-effects meta-analysis of the association summary statistics for 
16,095 directly genotyped SNPs on the X chromosome from the UK Biobank and 
the EGG meta-analysis using GWAMA46 (maximum n = 270,929). Genome-wide 
significance was defined as P < 6.6 × 10−9, as calculated by Kemp et al.47, which 
was similar to the thresholds calculated using permutations by Jones et al.48. A 
locus was defined as one or more SNPs reaching genome-wide significance within 
a region of the genome; two genome-wide-significant SNPs were defined as 
belonging to two separate loci if the distance between them was ≥500 kb. The lead 
SNP within each locus was the SNP with the smallest P value.
Several sensitivity analyses were conducted to confirm the quality of our 
meta-analysis results (see Supplementary Note for details). Univariate linkage 
disequilibrium score regression49 estimated the genomic inflation as 1.08, 
indicating that the majority of genome-wide inflation of the test statistics was 
due to polygenicity. To assess the impact of this inflation, we recalculated the 
association P values after adjusting the test statistics for the linkage disequilibrium 
score regression intercept (Supplementary Table 5).
COJO analysis to identify additional independent signals. Approximate COJO 
analysis13 was performed in GCTA50 using the European ancestry meta-analysis 
summary statistics to identify independent association signals attaining genome-
wide significance (P < 6.6 × 10−9). The linkage disequilibrium reference panel 
was made up of 344,246 unrelated UK Biobank participants defined by the UK 
Biobank as having British ancestry, and SNPs were restricted to those present in 
the Haplotype Reference Consortium (HRC) reference panel. At each locus, only 
SNPs labeled by GCTA as ‘independent’ and not in linkage disequilibrium with the 
original lead SNP (r2 < 0.05) were listed as secondary SNPs.
Trans-ethnic meta-analysis. To identify any further independent birth-weight-
associated SNPs, we conducted a trans-ethnic meta-analysis combining three 
components (Supplementary Fig. 1): (1) 80,745 individuals from the European 
ancestry component within the EGG consortium; (2) 12,948 individuals from 
nine studies within the EGG consortium from diverse ancestry groups: African 
American, Afro-Caribbean, Mexican, Chinese, Thai, Filipino, Surinamese, Turkish 
and Moroccan; and (3) 227,530 individuals of all ancestries from the UK Biobank. 
The same strategy and variant filtering criteria were applied as in the European 
meta-analysis (Supplementary Fig. 1). Univariate linkage disequilibrium score 
regression49 estimated the genomic inflation as 1.08. P values after adjustment 
of the test statistics for the linkage disequilibrium score regression intercept are 
presented in Supplementary Table 5.
GWAS of offspring birth weight. European ancestry meta-analysis. The European 
ancestry GWAS meta-analysis of offspring birth weight consisted of three 
components (Supplementary Fig. 2): (1) 12,319 individuals from 10 GWASs in 
the EGG consortium of European descent imputed up to the HapMap 2 reference 
panel; (2) 7,542 individuals from 2 GWASs in the EGG consortium of European 
descent imputed up to the HRC panel; and (3) 190,406 individuals of white 
European origin from the UK Biobank (see Supplementary Note for details on 
phenotype preparation and GWAS analyses). We conducted a European ancestry 
fixed-effects meta-analysis to combine the association summary statistics from 
the three components using GWAMA46 (max n = 210,267). We also performed 
a fixed-effects meta-analysis of the association summary statistics for 18,137 
directly genotyped SNPs on the X chromosome from the UK Biobank and EGG 
meta-analysis using GWAMA46 (max n = 197,093). The same strategy and variant 
filtering criteria were applied as in the meta-analysis of own birth weight, and the 
same sensitivity analyses were conducted (Supplementary Note).
Univariate linkage disequilibrium score regression49 estimated the genomic 
inflation as 1.05. We recalculated the P values after adjusting the test statistics for 
this linkage disequilibrium score intercept (Supplementary Table 5).
Approximate COJO analysis to identify additional independent signals. We 
performed approximate COJO analysis13 using the European ancestry meta-
analysis summary statistics of offspring birth weight. We used the same reference 
panel as in the own-birth-weight analysis and listed any secondary ‘independent’ 
SNPs associated with offspring birth weight.
Trans-ethnic meta-analysis. We conducted a trans-ethnic meta-analysis combining 
three components (Supplementary Fig. 2): (1) 12,319 individuals from 10 GWASs 
in the EGG consortium of European descent imputed up to the HapMap 2 
reference panel; (2) 7,542 individuals from 2 GWASs in the EGG consortium of 
European descent imputed up to the HRC panel; and (3) 210,208 individuals of all 
ancestries from the UK Biobank. The same strategy and variant filtering criteria 
were applied as in the European meta-analysis (Supplementary Fig. 2), and the 
same sensitivity analyses were conducted (Supplementary Note). Univariate linkage 
disequilibrium score regression49 estimated the genomic inflation as 1.04, and the 
recalculated P values after adjusting the test statistics for this linkage disequilibrium 
score intercept are presented in Supplementary Table 5.
Colocalization methods. For each signal where we identified different lead SNPs 
in the GWASs of own birth weight and offspring birth weight, we performed 
colocalization analysis using the ‘coloc’ R package51. For each signal, we input the 
regression coefficients, their variances, and SNP MAFs for all SNPs 500 kb up- and 
downstream of the lead SNP from the European meta-analysis. We used the coloc.
abf() function, with its default parameters, to calculate posterior probabilities that 
the own birth weight and offspring birth weight lead SNPs were independent (H3) 
or shared the same associated variant (H4). We called variants the same signal if 
the H4 posterior probability was greater than 0.50, and different signals if the H3 
posterior probability was greater than 0.50.
Estimation of genetic variance explained. First, we estimated the proportion of 
birth weight variance explained by fetal genotypes, maternal genotypes and the 
covariance between the two at the 190 genome-wide-significant signals in the 
Norwegian Mother and Child Cohort Study (MoBa–HARVEST; https://www.fhi.
no/en/studies/moba/). This sample was independent of samples contributing to the 
discovery meta-analyses, apart from a small potential overlap with mothers from the 
MoBa 2008 sample that was included in the GWAS of offspring birth weight (<0.07% 
of the meta-analysis sample). For the 19 signals that had different maternal and fetal 
lead SNPs, the fetal SNP (and not the maternal SNP) was used in the analysis to 
avoid collinearity in the model. We excluded multiple births, babies of non-European 
descent, babies born before 37 weeks of gestation, and babies born with a congenital 
anomaly or still-born. Birth weight was z-score transformed and all models were 
adjusted for sex, gestational duration and the first four ancestry-informative principal 
components. We conducted a linear regression analysis in R52 using 13,934 mother–
offspring pairs where offspring birth weight was regressed on the maternal and fetal 
genotypes at all 190 SNPs simultaneously. The proportion of variance explained by 
fetal genotypes at the 190 genome-wide-significant signals was calculated as:
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Where pi is the effect allele frequency of the ith SNP, βf̂i is the regression coefficient for the effect of the offspring’s genotype at the ith SNP on offspring birth weight, 
and var(BW) is the variance of offspring birth weight (which is approximately 1 as 
birth weight was z-score transformed). A similar formula was used to calculate the 
variance explained by maternal genotypes, using:
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Where βm̂i is the regression coefficient for the effect of the maternal genotype at 
the ith SNP on offspring birth weight. The following formula was used to calculate 
twice the covariance:
∑
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Second, we used maternal GCTA11 to estimate the proportion of variance in birth 
weight explained by genome-wide SNPs, or SNPs they tag, in the fetal genome or 
maternal genome, the covariance between the two and environmental factors in 
MoBa–HARVEST. The same phenotype was used as in the previous analysis and 
the model was adjusted for sex and gestational duration. Mothers or offspring were 
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excluded if they were related to others in the sample, using a genetic relationship 
cut-off of 0.025, leaving n = 7,910 mother–offspring pairs available for analysis.
Identifying eQTL-linked genes. We used FUSION53 with the v6p release of the 
GTEx data14 to identify eQTL-linked genes. FUSION incorporates information 
from gene expression and GWAS data to translate evidence of association with 
a phenotype from the SNP level to the gene. Only gene-level results from the 
adjusted model were taken forward for consideration. Each of the genes implicated 
by this analysis survived multiple testing correction (Bonferroni corrected 
P < 6 × 10−7, after adjusting for 44 tissues) and were independent from other 
proximal genes tested in a joint model.
Placenta eQTL look ups. We annotated genome-wide-significant birth-weight-
associated SNPs with gene expression data (200/209 SNPs available) from 
European ancestry placental samples in the Rhode Island Child Health Study15 
(n = 123 with a fetal genotype, including 71 with a birth weight appropriate for 
gestational age, 15 small for gestational age and 37 large for gestational age). SNPs 
were annotated if they had a genome-wide empirical false discovery rate < 0.01 for 
association with one or more transcripts, and r2 > 0.7 with a lead eQTL SNP.
TAD pathways. TAD pathway analysis was performed using software described in 
Way et al.16. Briefly, the software uses publicly available TAD boundaries, identified 
in human embryonic stem cells and fibroblasts using a hidden Markov model17, to 
prioritize candidate genes at GWAS SNPs. These TAD boundaries are stable across 
different cell types and can be used to identify genomic regions where non-coding 
causal variants are most likely to impact tissue-independent function.
Structural equation model for estimating adjusted maternal and fetal effects 
of the genome-wide-significant variants. The SEM approach used to estimate 
adjusted maternal and fetal effects has been described elsewhere12 (for additional 
details, see Supplementary Note).
The SEM was fit to data from 146 genome-wide-significant lead fetal SNPs and 
72 lead maternal SNPs from the GWAS meta-analysis (Supplementary Fig. 4). To 
identify a subset of unrelated individuals in the UK Biobank (as the SEM cannot 
easily account for relatedness), we generated a genetic relationship matrix using 
the GCTA software package50 (version 1.90.2) and excluded one of every pair of 
related individuals with a genetic relationship greater than 9.375%. After the same 
exclusions were made as in the GWAS, 85,518 unrelated individuals of European 
ancestry with their own and their offspring’s birth weight, 98,235 individuals with 
their own birth weight only, and 73,981 individuals with their offspring’s birth weight 
only were available for analysis. We fit linear regression models to birth weight and 
offspring birth weight in this subset of unrelated, European ancestry individuals 
adjusting for sex (own birth weight only), assessment center and the top 40 ancestry-
informative principal components provided by the UK Biobank, to account for any 
remaining population substructure. The residuals from these regression models 
were z-score transformed for analysis. Because we included the summary statistics 
from the meta-analysis of the EGG studies, rather than the individual-level data, we 
were unable to account for the small of subset individuals who contributed to both 
the own-birth-weight and offspring-birth-weight GWAS meta-analyses. Based on 
the results from simulations (not shown), we expect that this non-independence 
will result in very slightly smaller standard errors and an increased type 1 error rate, 
particularly for the fetal effect, which is estimated from a larger sample size than 
was available to estimate the maternal effect. Therefore, we conducted a sensitivity 
analysis that first excluded EGG studies from the meta-analysis of own birth 
weight that contributed to both GWAS meta-analyses of own and offspring birth 
weight (for example, ALSPAC), and then refitted the non-overlapping data in the 
SEM; these results are presented in Supplementary Table 19. For SNPs identified 
on the X chromosome, we fit a slightly different SEM due to males having double 
the expected genetic variance at X-linked loci compared with females. We did not 
incorporate summary statistics from the EGG Consortium as the GWAS results were 
not stratified according to sex (additional details on the X chromosome analysis are 
provided in the Supplementary Note and Supplementary Fig. 6b).
We used the estimates from the SEM to classify the lead SNPs into the following 
five categories. (1) Fetal only: the 95% CI surrounding the fetal effect estimate 
does not overlap zero and does not overlap the 95% CI around the maternal 
effect estimate. Additionally, the 95% CI surrounding the maternal effect estimate 
overlaps zero. (2) Maternal only: the 95% CI surrounding the maternal effect 
estimate does not overlap zero and does not overlap the 95% CI around the fetal 
effect estimate. Additionally, the 95% CI surrounding the fetal effect estimate 
overlaps zero. (3) Fetal and maternal, with effects going in the same direction: the 
95% CIs around both the maternal and fetal effect estimates do not overlap zero, 
and their effect is in the same direction. (4) Fetal and maternal, with effects going in 
opposite directions: the 95% CIs around both the maternal and fetal effect estimates 
do not overlap zero, and their effects are in opposite directions. (5) Unclassified: 
SNPs do not fall into any of these categories; therefore, the 95% CIs around the 
maternal and fetal effect estimates overlap, and at least one overlaps zero.
Meta-analysis of maternal and fetal effects from a conditional regression 
analysis in mother–offspring pairs. We conducted conditional association 
analyses for all 209 lead SNPs in 18,873 mother–offspring pairs from 3 studies 
(MoBa–HARVEST, ALSPAC and EFSOCH), adjusting for both maternal and 
offspring genotype, and combined the summary statistics for each SNP in a fixed-
effects meta-analysis using METAL54. We compared the estimates of the maternal 
and fetal effects of this meta-analysis with the SEM-adjusted maternal and fetal 
effects using a heterogeneity test (Supplementary Table 6).
Approximation of the SEM for genome-wide analyses. The SEM is 
computationally intensive to fit, making it difficult to run on all SNPs across the 
genome. Therefore, we developed an approximation of the SEM using a linear 
transformation and ordinary least squares linear regression, which we refer to as 
WLM-adjusted analyses. The full details of the derivation are provided in  
the Supplementary Note. Briefly, from ordinary least squares regression, we know 
that the estimated fetal effect size from the GWAS of own birth weight, βf̂unadj,  
is calculated by dividing the sample covariance between birth weight and SNP 
by the sample variance of the SNP. Similarly, the estimated maternal effect from 
the GWAS of offspring birth weight, βm̂unadj, is calculated by dividing the sample 
covariance between offspring birth weight and SNP by the sample variance of 
the SNP. It follows that an estimate of the fetal effect adjusted for the maternal 
genotype is (see Supplementary Note for full derivation):
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3
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and an estimate of the maternal effect adjusted for the fetal genotype is:
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If the model is truly linear, the same estimates can be obtained by transforming 
the reported birth weights rather than the regression coefficients55. See the 
Supplementary Note and Supplementary Fig. 18 for a flow diagram of the full 
analysis pipeline. A comparison of the results using this WLM method and the full 
SEM for the lead SNPs is presented in Supplementary Fig. 9.
Gene expression integration. To identify which tissue types were most relevant to 
genes involved in birth weight, we applied linkage disequilibrium score regression 
to specifically expressed genes (‘LDSC-SEG’)19. We used the summary statistics 
from the GWAS meta-analysis of own and offspring birth weight and the WLM-
adjusted meta-analyses. Briefly, the method takes each tissue, ranking genes by a  
t statistic for differential expression, using sex and age as covariates, and excluding 
all samples in related tissues. It then takes the top 10% of ranked genes and makes a 
genome annotation including these genes (exons and introns) plus 100 kb on either 
side. Finally, it uses stratified linkage disequilibrium score regression to estimate 
the contribution of this annotation to per-SNP birth weight heritability, adjusting 
for all categories in the baseline model. We computed significance using a block 
jackknife over SNPs, and corrected for the number of tissues tested.
Gene-set enrichment analysis (MAGENTA). Pathway-based associations 
using summary statistics from the GWAS meta-analysis of own and offspring 
birth weight and WLM-adjusted meta-analysis were tested using MAGENTA56. 
Briefly, the software maps each gene to the SNP with the lowest P value within a 
110-kb upstream and 40-kb downstream window. This P value is corrected for 
factors such as SNP density and gene size using a regression model. Genes within 
the HLA region were excluded. The observed number of gene scores within a 
given pathway with a ranked gene score above a given threshold (ninety-fifth or 
seventy-fifth percentile) was calculated. This statistic was compared with 1,000,000 
randomly permuted pathways of the same size to calculate an empirical P value 
for each pathway. We considered pathways with a false discovery rate < 0.05 to be 
of interest. The 3,230 biological pathways tested were from the BIOCARTA, Gene 
Ontology, KEGG, PANTHER and READTOME databases, along with a small 
number of custom gene sets.
Gestational duration associations. We extracted the 209 lead birth-weight-
associated SNPs from the summary statistics provided by 23andMe and published 
in a recent GWAS of gestational duration20. Any birth weight-associated SNP that 
was also associated with gestational duration (P < 2.4 × 10−4, corrected for 209 tests) 
was followed up in 13,206 mother–child pairs from the MoBa–HARVEST, ALSPAC 
and EFSOCH studies. Preterm births (gestational duration < 37 weeks) were 
removed before analysis, and gestational duration and birth weight were both z-
score transformed. We conducted linear regression analyses to test the association 
between maternal or fetal genotype (both unadjusted and adjusted genotype 
effects) and gestational duration, birth weight or gestational duration adjusted 
for birth weight. The association analysis results were combined using inverse-
variance-weighted meta-analysis. We also combined the unadjusted maternal 
SNP-gestational duration associations with the 23andMe summary statistics20 using 
P value-based meta-analysis implemented in METAL54.
Association between birth-weight-associated SNPs and a variety of traits. 
We performed GWASs on 78 traits in the UK Biobank using BOLT-LMM in an 
analogous way to the analysis of own birth weight. Phenotype definitions for the 
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78 traits are described by Frayling et al.57. Association statistics for the 209 lead 
birth-weight-associated SNPs were then extracted from the results (Supplementary 
Table 13). Additionally, we searched the NHGRI GWAS (https://www.ebi.ac.uk/
gwas/; accessed 16 January 2018) for the 209 lead birth-weight-associated SNPs, or 
SNPs in high linkage disequilibrium with the 209 lead SNPs (r2 > 0.8), and reported 
associations with other traits (Supplementary Table 13).
Linkage disequilibrium score regression. Linkage disequilibrium score regression, 
which has been described in detail elsewhere18, was used to estimate the genetic 
correlation between birth weight and a range of traits and diseases. We used 
LD Hub58 (ldsc.broadinstitute.org/) to perform the linkage disequilibrium score 
regression analyses. Due to the different linkage disequilibrium structure across 
ancestry groups, the summary statistics from the European-only birth weight 
analyses were uploaded to LD Hub, and genetic correlations were calculated with 
all available phenotypes. We conducted four separate analyses in LD Hub using (1) 
GWAS meta-analysis of own birth weight; (2) GWAS meta-analysis of offspring 
birth weight; (3) WLM-adjusted fetal effect; and (4) WLM-adjusted maternal effect.
To calculate the genetic correlation between the maternal and fetal effect 
estimates from the unadjusted and WLM-adjusted analyses, and also between 
gestational duration and the WLM-adjusted maternal and fetal effects, we used the 
scripts provided by the developer (https://github.com/bulik/ldsc).
Mendelian randomization analyses of maternal and fetal exposures on offspring 
birth weight. Two-sample Mendelian randomization analyses were performed with 
own or offspring birth weight as outcomes. The exposures included height, fasting 
glucose, disposition index of insulin secretion59, insulin sensitivity, SBP and DBP. 
The SNP–exposure associations were taken from external studies (Supplementary 
Table 14). The SNP–outcome associations were taken from the current European 
GWAS meta-analyses of own birth weight, offspring birth weight, WLM-
adjusted fetal effect and WLM-adjusted maternal effect. Two-sample Mendelian 
randomization regresses the effect sizes of SNP–outcome associations against 
the effect sizes of SNP–exposure associations, with an inverse-variance weighted 
analysis, giving similar results to the two-stage least-squares analysis in a single 
sample60. We performed several sensitivity analyses to assess the impact of genetic 
pleiotropy on the causal estimates including MR-Egger61, Weighted Median62 and 
Penalized Weighted Median62 (see Supplementary Table 15 for results). Details of 
the R code for the Mendelian randomization analyses are provided elsewhere61,62.
Due to the strong negative correlation between estimates of the maternal and 
fetal genetic effects on birth weight, we conducted simulations to confirm that 
this correlation did not bias the results of downstream Mendelian randomization 
analyses; these simulations are described in the Supplementary Note.
Transmitted/non-transmitted allele scores in ALSPAC. Allelic transmission 
was determined for 4,962 mother–offspring pairs in ALSPAC. First, we converted 
maternal and fetal genotypes into best-guess genotypes where SNPs of interest had 
been imputed. Where one or both of the mother–offspring pair were homozygous, 
allelic transmission was trivial to determine. Where both mother and offspring 
were heterozygous for the SNP of interest, we used phase imputation generated 
using SHAPEIT2 (ref. 63) to examine the haplotypes in the region of the SNP of 
interest to determine allelic transmission. Weighted allele scores were generated for 
maternal non-transmitted, shared (maternal transmitted) and paternally inherited 
fetal alleles for SBP, DBP, fasting glucose, insulin secretion and insulin sensitivity. 
Associations were tested between the weighted allele scores and birth weight.
Covariance between birth weight and adult traits explained by genotyped 
SNPs. The genetic and residual covariance between birth weight and several 
quantitative/disease phenotypes was calculated in the UK Biobank using REML 
in BOLT-LMM64. We included 215,444 individuals of European ancestry with 
data on own birth weight and 190,406 with data on offspring birth weight. SNPs 
with MAF < 1%, evidence of deviation from Hardy–Weinberg equilibrium 
(P ≤ 1 × 10−6) or an overall missing rate > 0.015 were excluded, resulting in 524,307 
genotyped SNPs for analysis. We then calculated 96% CIs for the proportion of 
covariance explained by genotyped variants as gcov/(gcov + rcov) ± 1.96 × gcovSE/
abs(gcov + rcov), where gcov is genetic covariance, rcov is the residual covariance, 
gcovSE is the standard error for gcov, and abs is the absolute value. Details of the 
phenotype preparation for the adult traits are provided in the Supplementary Note.
Association between maternal SNPs associated with offspring birth weight 
and later-life offspring SBP. Using the UK Biobank, we tested whether maternal 
SNPs associated with offspring birth weight were also associated with offspring 
SBP in later life. The UK Biobank released kinship information generated in 
KING65, which included kinship coefficients and estimates of the proportion 
of SNPs with zero identical-by-state (IBS0). We defined parent–offspring pairs 
using the kinship coefficient and IBS0 cut-offs recommended by Manichaikul 
et al.65. There were 5,635 unique parent–offspring pairs of European ancestry with 
SBP data (for parents who had multiple offspring with SBP data, only the oldest 
offspring was included in the analysis); 3,886 mother–offspring pairs and 1,749 
father–offspring pairs. We tested the relationship between unweighted allelic 
scores of birth-weight-associated SNPs in mothers/fathers and offspring SBP (see 
Supplementary Note for SBP phenotype preparation) before and after adjusting 
for offspring genotypes at the same loci. We examined unweighted allelic scores 
consisting of all autosomal lead birth-weight-associated SNPs available in the 
UK Biobank (205 SNPs), 72 autosomal SNPs that showed evidence of a maternal 
effect and 31 autosomal SNPs that showed evidence only of maternal effects 
on birth weight. We also looked at the SNPs previously associated with SBP 
(Supplementary Table 14) as a sensitivity analysis to rule out the possibility of 
postnatal pleiotropic effects contaminating our results. All analyses were adjusted 
for offspring age at SBP measurement, sex and assessment center.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
The genotype and phenotype data are available on application from the UK 
Biobank (http://www.ukbiobank.ac.uk/). Individual cohorts participating in the 
EGG Consortium should be contacted directly as each cohort has different data 
access policies. GWAS summary statistics from this study are available via the EGG 
website (https://egg-consortium.org/).
code availability
Custom-written code is available on request from N.M.W. (e-mail: n.warrington@
uq.edu.au).
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provide detailed supplementary tables with characteristics of each study and references to study descriptions.
Data analysis We used BOLT-LMM (version 2.3.2), GWAMA (version 2.2.2), GCTA (version 1.91.1), FUSION (version released 1 Dec 2016), TAD pathway 
analysis (accessed on 3 Nov 2017), METAL (version released 25 March 2011), LDSC-SEG (using LDSC version 1.0.0), MAGENTA (version 
2.4), LD Hub (version 1.9.0), Coloc (version 3.1), Stata (version 13.0 and 14.0), LDlink (version 3.0) and R to analyse the data and produce 
plots for this manuscript. A full description of software used in this paper is provided in the Methods section, along with references to 
the relevant journal articles.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers 
upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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Data
Policy information about availability of data
All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: 
- Accession codes, unique identifiers, or web links for publicly available datasets 
- A list of figures that have associated raw data 
- A description of any restrictions on data availability
The following Data Availability statement is included in the manuscript: 
Data availability 
The genotype and phenotype data are available upon application from the UK Biobank (http://www.ukbiobank.ac.uk/). Individual cohorts participating in the EGG 
consortium should be contacted directly as each cohort has different data access policies. GWAS summary statistics from this study are available via the EGG 
website (https://egg-consortium.org/).
Field-specific reporting
Please select the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
Life sciences Behavioural & social sciences  Ecological, evolutionary & environmental sciences
For a reference copy of the document with all sections, see nature.com/authors/policies/ReportingSummary-flat.pdf
Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size Full descriptions of how we defined the samples included in the GWAS of own or offspring birth weight are included in the methods section. 
Briefly, we aimed to bring together the largest possible sample size with birth weight and/or offspring birth weight and GWAS data to study 
the role of genetic variation in birth weight. We excluded some individuals, as described below, and the final sample size was then the 
number of individuals included in any given statistical test that had no missing data for all genotype and phenotype variables included in the 
model. These numbers are given clearly in the main body of the article and the Methods section. Our sample size was adequate to recover the 
65 known birth weight associated regions and identify 129 novel independent association signals. Additionally, as mentioned in the results 
section, asymptotic power calculations showed that with our sample size we had 80% power to detect fetal (maternal) effects that explained 
0.006% (0.008%) of the variance in birth weight (α=0.05). 
Data exclusions Established protocols were used to conduct rigorous data quality control for each study prior to the GWAS analyses.  
The following exclusions were made for the birth weight phenotype: i) twins and other multiple births, ii) individuals born before 37 weeks of 
gestation (where gestational duration was available), iii) any extreme outliers in the birth weight distribution, iv) babies born with congenital 
anomalies (where available). In the UK Biobank, where there was no gestational duration information, we included only individuals born 
between 2.5 and 4.5kg. Within each genotyped dataset, to guard against population stratification, principal components analysis was used to 
exclude ancestry outliers (for example, the European component of the UK Biobank was defined using k-means cluster analysis, described in 
the Methods section).  
In the EGG studies, SNPs were excluded if the INFO<0.4, minimac r2<0.3 or minor allele count was <3. In the UK Biobank, SNPs were excluded 
if the INFO<0.3, minor allele frequency was <0.1% or they were not HRC imputed SNPs.  
Additional data exclusions for individual studies are provided in Supplementary Tables 1-4.
Replication To determine the overall evidence of association at each SNP, we performed a meta-analysis of available GWAS studies. We checked for 
evidence of heterogeneity between the European component of the UK Biobank and the EGG European component to verify that there was 
consistency between the major components of the meta-analysis. This is described in the manuscript.
Randomization Individuals in the UK Biobank were not assigned to specific groups, but data and samples were collected at different study centres and were 
genotyped in batches and on different arrays. Strict quality control performed centrally by UK Biobank ensured that batch-effects were 
controlled for in the genotype data. We adjusted genetic association tests for both study centre and data release (see Methods section for 
detail). 
We performed Mendelian randomization analyses, based on the assumption that genotype is randomly assigned at conception and thus that 
the maternal genotype can be used as an unconfounded proxy for a maternal characteristic, such as glucose, height etc. Essentially, using this 
method (with appropriate control for fetal genotype), birth weight is assessed in individuals effectively randomized to different maternal 
glucose/height etc levels. The Methods are described in detail in the manuscript.
Blinding Data collected by both UK Biobank and EGG studies were observational and had no specific interventions. As such, no blinding was required.
Reporting for specific materials, systems and methods
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Materials & experimental systems
n/a Involved in the study
Unique biological materials
Antibodies
Eukaryotic cell lines
Palaeontology
Animals and other organisms
Human research participants
Methods
n/a Involved in the study
ChIP-seq
Flow cytometry
MRI-based neuroimaging
Human research participants
Policy information about studies involving human research participants
Population characteristics The UK Biobank is a cohort of British residents between the ages of 37 and 73, recruited to 22 centres at baseline measurement. 
Of the European-ancestry individuals who reported their own birth weight, 61% of participants were women. The EGG 
Consortium studies are mainly birth cohort designs, in which parent participants were recruited in pregnancy. Analyses of 
offspring birth weight (maternal GWAS) contained all women. In the UK Biobank, sex of the baby was not known; in the EGG 
Consortium studies, the male/female ratio of offspring was approx. 50/50. More details are provided in the supplementary 
tables and references. Participants were not selected on the basis of disease status.
Recruitment The EGG Consortium studies are mainly birth cohort designs, in which parent participants were recruited in pregnancy and/or 
offspring at birth. Details are given in the supplementary tables and references. The UK Biobank consists of participants recruited 
in middle-age, and birth weight data are recalled and self-reported. We have shown previously that the self-reported variable is 
associated as expected with factors like sex, maternal age and height (Tyrrell et al 2013 IJE) and that genetic associations with 
birth weight are similar in the UK Biobank and EGG Consortium birth cohorts with measured birth weight (Horikoshi et al Nature 
2016, and current manuscript), so we do not consider the self-report data to be a problem, especially given the large sample 
size. We note that the UK Biobank had a low response rate (5%), so we cannot rule out potential bias from selection, for 
example, resulting in higher average socio-economic position. 
